Development of an MRM assay panel with application to biobank samples from patients with myocardial infarction

Journal of Proteomics

Volumn 87, Issue , 2013, Pages 16-25

  Rezeli, Melinda ^a   Végvári, Ákos ^a   Donnarumma, Fabrizio ^a   Gidlöf, Olof ^b   Smith, J Gustav ^b   Erlinge, David ^b   Marko Varga, György ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Apolipoproteins; Multiple reaction monitoring; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN D; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA2 GLYCOPROTEIN 1; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PROTEIN; SERINE PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ARTICLE; ASSAY; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; HEART INFARCTION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING ASSAY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

APOLIPOPROTEINS; BIOLOGICAL SPECIMEN BANKS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MYOCARDIAL INFARCTION; REPRODUCIBILITY OF RESULTS;

EID: 84878898726     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.05.016     Document Type: Article

References (26)

1. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren W.M.M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol 2012, 19:585-667.
2. Addona T.A., Shi X., Keshishian H., Mani D.R., Burgess M., Gillette M.A., et al. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol 2011, 29:635-U119.
3. Gerszten R.E., Asnani A., Carr S.A. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res 2011, 109:463-474.
4. Huttenhain R., Malmstrom J., Picotti P., Aebersold R. Perspectives of targeted mass spectrometry for protein biomarker verification. Curr Opin Chem Biol 2009, 13:518-525.
5. Rodriguez H., Rivers R., Kinsinger C., Mesri M., Hiltke T., Rahbar A., et al. Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective. Proteomics Clin Appl 2010, 4:904-914.
6. Whiteaker J.R. The increasing role of mass spectrometry in quantitative clinical proteomics. Clin Chem 2010, 56:1373-1374.
7. Anderson N.L., Jackson A., Smith D., Hardie D., Borchers C., Pearson T.W. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009, 8:995-1005.
8. Kuhn E., Addona T., Keshishian H., Burgess M., Mani D.R., Lee R.T., et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009, 55:1108-1117.
9. Razavi M., Frick L.E., LaMarr W.A., Pope M.E., Miller C.A., Anderson N.L., et al. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res 2012, 11:5642-5649.
10. Lopez M.F., Rezai T., Sarracino D.A., Prakash A., Krastins B., Athanas M., et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010, 56:281-290.
11. Wang M., Chen J., Turko I.V. N-15-labeled full-length apolipoprotein E4 as an internal standard for mass spectrometry quantification of apolipoprotein E isoforms. Anal Chem 2012, 84:8340-8344.
12. Kay R.G., Gregory B., Grace P.B., Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun Mass Spectrom 2007, 21:2585-2593.
13. Domanski D., Percy A.J., Yang J., Chambers A.G., Hill J.S., Freue G.V.C., et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 2012, 12:1222-1243.
14. Gerszten R.E., Carr S.A., Sabatine M. Integration of proteomic-based tools for improved biomarkers of myocardial injury. Clin Chem 2010, 56:194-201.
15. Agger S.A., Marney L.C., Hoofnagle A.N. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple-reaction-monitoring mass spectrometry. Clin Chem 2010, 56:1804-1813.
16. McQueen M.J., Hawken S., Wang X.Y., Ounpuu S., Sniderman A., Probstfield J., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
17. Holme I., Aastveit A.H., Hammar N., Jungner I., Walldius G. Lipoprotein components and risk of congestive heart failure in 84740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Eur J Heart Fail 2009, 11:1036-1042.
18. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
19. Rezeli M., Vegvari A., Otteruald J., Olsson T., Laurell T., Marko-Varga G. MRM assay for quantitation of complement components in human blood plasma - a feasibility study on multiple sclerosis. J Proteomics 2011, 75:211-220.
20. MacLean B., Tomazela D.M., Abbatiello S.E., Zhang S., Whiteaker J.R., Paulovich A.G., et al. Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. Anal Chem 2010, 82:10116-10124.
21. Lange V., Picotti P., Domon B., Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4.
22. Kuzyk M.A., Smith D., Yang J.C., Cross T.J., Jackson A.M., Hardie D.B., et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009, 8:1860-1877.
23. Vaisar T., Pennathur S., Green P.S., Gharib S.A., Hoofnagle A.N., Cheung M.C., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
24. Ken-Dror G., Talmud P.J., Humphries S.E., Drenos F. APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men. Mol Med 2010, 16:389-399.
25. Surinova S., Schiess R., Huttenhain R., Cerciello F., Wollscheid B., Aebersold R. On the development of plasma protein biomarkers. J Proteome Res 2011, 10:5-16.
26. Paulovich A.G., Whiteaker J.R., Hoofnagle A.N., Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008, 2:1386-1402.